Published in:
Open Access
01-12-2015 | Review
Mesenchymal stromal cells to modulate immune reconstitution early post-hematopoietic cell transplantation
Authors:
Elizabeth O. Stenger, Lakshmanan Krishnamurti, Jacques Galipeau
Published in:
BMC Immunology
|
Issue 1/2015
Login to get access
Abstract
Mesenchymal stromal cells (MSCs) are multipotent progenitor cells known to modulate the immune system and to promote hematopoiesis. These dual effects make MSCs attractive for use as cellular therapy in hematopoietic cell transplantation (HCT). MSCs can be used peri-HCT or pre-engraftment to modulate immune reconstitution, promoting hematopoietic stem cell (HSC) engraftment and/or preventing graft-versus-host disease (GVHD). Pre-clinical studies have demonstrated that MSCs can potentiate HSC engraftment and prevent GVHD in a variety of animal models. Clinical trials have been small and largely non-randomized but have established safety and early evidence of efficacy, supporting the need for larger randomized trials.